Q-omics provides the consensus-scored VPS37D profile across patient tissues and cancer cell-line models. VPS37D expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VPS37D is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, VPS37D RNA expression shows 17,533 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LUAD, and GBM as cancer lineages where VPS37D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS37D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS37D survival associations across molecular data types. VPS37D RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS37D RNA expression–survival associations across cancer types. High VPS37D expression shows unfavorable associations in ACC, COAD, MESO and ESCA, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for VPS37D RNA expression.
This table summarizes VPS37D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS37D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS37D shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LUAD, COAD and LIHC. The LUAD box plot shows higher VPS37D RNA expression in tumor versus normal tissue (log2 FC = +2.135, t-test p < 0.001).
This table shows molecular features associated with VPS37D in patient tissues and cancer cell lines. In patient samples, VPS37D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS37D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
